thin filament4inked regulatory protein caldesmon and to determine how the interplay between thin-filament-linked and thick-filament-linked systems regulates the level of cross bridge activation (force production) and the rate of cross bridge cycling (unloaded shortening velocity). The proposed studies will test the hypothesis that the actin-binding protein, caldesmon, is a major component of an actin-linked regulatory system which meddles the activation of contraction which occurs in response to myosin phosphorylation. The proposed studies will specifically test the hypothesis that caldesmon modulates both cross bridge cycling rates and the number of attached cross bridges at any given level of myosin phosphorylation. These studies will also test the hypothesis that both calcium-calmodulin and caldesmon phosphorylation regulate the effects of caldesmon. The experimental approach will involve measurement of caldesmon phosphorylation and mechanical parameters for pharmacologically activated smooth muscle. In addition, the levels of caldesmon and myosin phosphorylation will be manipulated in chemically permeabilized (skinned) muscles while measuring the effects on contractile properties (i.e. shortening velocity and force development). Phosphopeptide mapping, phosphoamino analysis, and gas phase microsequencing will be used to analyze the phosphorylation sites on caldesmon. In collaboration with project #3, an in vitro actin-motility assay will also be used to determine what effects caldesmon, phosphocaldesmon, and calcium-calmodulin have on the translation velocity of actin filaments over a myosin surface. Lastly, the distribution of caldesmon among native actin filaments isolated from tonic, vascular, and pha3ic, nonvascular smooth muscle will be measured to determine d there are caldesmon-free populations of actin in smooth muscles. These studies will not only verity that caldesmon plays a regulatory role in smooth muscle but will also provide significant new information about the mechanisms underlying this regulatory process and about the involvement of caldesmon in the formation of latch bridges in vascular smooth muscles.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL028001-11
Application #
3844127
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
11
Fiscal Year
1992
Total Cost
Indirect Cost
Name
University of Vermont & St Agric College
Department
Type
DUNS #
066811191
City
Burlington
State
VT
Country
United States
Zip Code
05405
Peterson, J N; Nassar, R; Anderson, P A et al. (2001) Altered cross-bridge characteristics following haemodynamic overload in rabbit hearts expressing V3 myosin. J Physiol 536:569-82
Peterson, J N; Alpert, N R (1998) Cross-bridge dynamics in the contracting heart. Adv Exp Med Biol 453:117-23;discussion 123-4
Alpert, N R; Mulieri, L A (1997) Human heart failure: determinants of ventricular dysfunction. Adv Exp Med Biol 430:97-108
Peterson, J N; Alpert, N R (1996) Molecular motor mechanics in the contracting heart. V1 versus V3 myosin heavy chain. Ann N Y Acad Sci 793:54-63
VanBuren, P; Harris, D E; Alpert, N R et al. (1995) Cardiac V1 and V3 myosins differ in their hydrolytic and mechanical activities in vitro. Circ Res 77:439-44
Laporte, R; Haeberle, J R; Laher, I (1994) Phorbol ester-induced potentiation of myogenic tone is not associated with increases in Ca2+ influx, myoplasmic free Ca2+ concentration, or 20-kDa myosin light chain phosphorylation. J Mol Cell Cardiol 26:297-302
Hemric, M E; Tracy, P B; Haeberle, J R (1994) Caldesmon enhances the binding of myosin to the cytoskeleton during platelet activation. J Biol Chem 269:4125-8
Fisher, S A; Periasamy, M (1994) Collagen synthesis inhibitors disrupt embryonic cardiocyte myofibrillogenesis and alter the expression of cardiac specific genes in vitro. J Mol Cell Cardiol 26:721-31
Haeberle, J R; Hemric, M E (1994) A model for the coregulation of smooth muscle actomyosin by caldesmon, calponin, tropomyosin, and the myosin regulatory light chain. Can J Physiol Pharmacol 72:1400-9
Haeberle, J R (1994) Calponin decreases the rate of cross-bridge cycling and increases maximum force production by smooth muscle myosin in an in vitro motility assay. J Biol Chem 269:12424-31

Showing the most recent 10 out of 32 publications